Core Viewpoint - vTv Therapeutics (VTVT) has shown a significant price increase of 41.4% over the past four weeks, with a mean price target of $37 indicating a potential upside of 25.2% from the current price of $29.56 [1] Price Targets and Analyst Consensus - The average price target for VTVT ranges from a low of $35.00 to a high of $40.00, with a standard deviation of $2.65, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates an 18.4% increase, while the highest suggests a 35.3% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about VTVT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 9.2% over the past month, with no negative revisions reported [12] - VTVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can often mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Ocular Therapeutix (OCUL) shares have increased by 6.7% recently, with a mean price target of $22.08 suggesting a potential upside of 82.5% from the current price of $12.1 [1] Price Targets - The average of 12 short-term price targets ranges from a low of $18.00 to a high of $31.00, with a standard deviation of $4.23, indicating variability among analysts [2] - The lowest estimate suggests a 48.8% increase, while the highest points to a 156.2% upside [2] Analyst Consensus - There is strong agreement among analysts regarding OCUL's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with five estimates increasing and no negative revisions [12] Zacks Rank - OCUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Earnings Estimate Revisions - Increasing optimism among analysts about OCUL's earnings prospects is reflected in the upward revisions of EPS estimates, which have a strong correlation with near-term stock price movements [11]

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) shows significant upside potential, with a mean price target of $41.38 indicating an 87.5% increase from the current trading price of $22.07 [1] Price Targets - The average of eight short-term price targets ranges from a low of $33.00 to a high of $52.00, with a standard deviation of $6.52, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 49.5%, while the highest suggests a 135.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about ELVN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 4.1% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Price Movement Guidance - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Group 1 - Lexeo Therapeutics, Inc. (LXEO) shares have increased by 3.9% over the past four weeks, closing at $8.52, with a mean price target of $19.11 indicating a potential upside of 124.3% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $6.6, where the lowest estimate is $9.00 (5.6% increase) and the highest is $30.00 (252.1% increase) [2] - Analysts show strong agreement on LXEO's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for LXEO's current year earnings has increased by 16.1% over the last 30 days, with four estimates moving higher and no negative revisions [12] - LXEO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate the direction of price movement, which appears to be a useful guide [14]

Core Viewpoint - Adma Biologics (ADMA) shows significant upside potential with a mean price target of $30.67, indicating a 108.5% increase from the current trading price of $14.71 [1][2]. Price Targets - The average price target consists of three estimates ranging from $30.00 to $32.00, with a standard deviation of $1.15, suggesting a consensus among analysts [2]. - The lowest estimate indicates a potential increase of 103.9%, while the highest suggests a 117.5% upside [2]. Analyst Sentiment - Analysts are optimistic about ADMA's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 1.6% due to one upward revision and no negative revisions in the last 30 days [12]. Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - While price targets are a common metric, they should be approached with skepticism as they can often mislead investors [3][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Core Viewpoint - Orion Energy Systems, Inc. (OESX) has shown a significant price increase of 26.6% over the past four weeks, with a mean price target of $17.83 indicating a potential upside of 75.2% from the current price of $10.18 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $2.57, where the lowest estimate of $15.00 suggests a 47.4% increase, and the highest estimate of $20.00 indicates a potential surge of 96.5% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts about OESX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 42.3% over the past month, with no negative revisions, indicating positive sentiment [12] - OESX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in price predictions by analysts [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8] - Investors should approach price targets with skepticism and consider them as one of many factors in their decision-making process [10]

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows significant potential for upside, with a current stock price of $24.01 and a mean price target of $30.38, indicating a 26.5% upside potential [1]. Price Targets - The average of eight short-term price targets ranges from a low of $29.00 to a high of $32.00, with a standard deviation of $1.19, suggesting a relatively high agreement among analysts [2]. - The lowest estimate indicates a potential increase of 20.8%, while the most optimistic estimate points to a 33.3% upside [2]. Analyst Sentiment - Analysts are increasingly optimistic about ARQT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has historically correlated with stock price movements [4][11]. - Over the last 30 days, three earnings estimates have been revised higher, leading to a 46.5% increase in the Zacks Consensus Estimate for the current year [12]. Zacks Rank - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which further supports the stock's potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the magnitude of ARQT's potential gains, the direction implied by these targets appears to be a useful guide for further research [14].

Group 1 - Relay Therapeutics, Inc. (RLAY) shares have increased by 37.4% over the past four weeks, closing at $7.31, with a mean price target of $13.6 indicating a potential upside of 86.1% [1] - The average of 10 short-term price targets ranges from a low of $4.00 to a high of $19.00, with a standard deviation of $4.22, suggesting variability in analyst estimates [2] - Analysts have shown increasing optimism regarding RLAY's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for RLAY's current year earnings has increased by 2% over the last 30 days, indicating a positive outlook [12] - RLAY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Shares of Ategrity Specialty Insurance Company Holdings (ASIC) have gained 1.8% over the past four weeks to close the last trading session at $19.54, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.8 indicates a potential upside of 32%.The average comprises five short-term price targets ranging from a low of $23.00 to a high of $30.00, with a standard deviation of $2.95. Whi ...

Core Viewpoint - Nektar Therapeutics (NKTR) shows potential for significant upside, with a mean price target of $93.86 indicating a 50% increase from its current price of $62.57, supported by positive earnings estimate revisions [1][11]. Price Targets and Analyst Consensus - The average price target for NKTR ranges from a low of $30.00 to a high of $120.00, with a standard deviation of $29.13, indicating variability in analyst estimates [2]. - The lowest estimate suggests a decline of 52.1%, while the highest points to a potential upside of 91.8% [2]. - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about NKTR's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has risen by 2.9% over the past month, with no negative revisions [12]. - NKTR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements accurately [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].